<DOC>
	<DOCNO>NCT01757613</DOCNO>
	<brief_summary>In three-armed dose-finding trial 3 AK 3012 topical formulation shall investigate respect safety efficacy order identify optimal concentration topical formulation . The main objective trial determine optimal concentration active agent topical formulation quantify change number skin alteration pre-defined area time period inclusion trial end treatment ( 3 month ) prior complete healing .</brief_summary>
	<brief_title>Study Whose Purpose Find Optimal Dose Treatment With AK 3012 Patients With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Age : â‰¥ 18 year Gender : male female Actinic Keratosis ( Olsen grade I/II ) least 5 actinic keratoses scalp , forehead , face , extremity , and/ decollete treatment actinic keratoses within previous 3 month inclusion study histologic confirmation diagnosis actinic keratosis biopsy good general condition normal laboratory value ( creatinine , urea , GlutamateOxalacetate Transaminase ( GOT ) , GlutamatePyruvate Transaminase ( GPT ) , gammaglutamyl transferase ( GGT ) , Lactate dehydrogenase ( LDH ) ) blood count study start high 1.5 x upper norm limit Female patient must test negative pregnancy inclusion trial . During trial , female patient apply generally accept form birth control ( i.e . oral estrogen gestagen contain contraceptive ; estrogen contain skin plaster/ tape , hormone implant , hormone contraceptive coil , sterilisation ; sexual abstinence ) postmenopausal least 2 year . Willing able participate screen trial specific procedure compliance protocol Signed write informed consent Known allergy nonsteroidal antiphlogistics and/ excipients investigational medicinal product Presence immunosuppression Treatment 5fluorouracil , cyclosporine , retinoids , glycolic acid , imiquimod , trichloroacetic acid trial 12 week inclusion trial Continuous treatment nonsteroidal antiphlogistics exception lowdose acetylsalicylic acid ( 100 mg ) inhibition thrombocyte aggregation Planned treatment photodynamic therapy participation trial Pregnancy lactation Participation another clinical trial within 3 month inclusion current trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>